1921
Volume 102, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Internet-facilitated self-diagnosis and treatment is becoming more prevalent, putting individuals at risk of toxicity when drugs are acquired without medical oversight. We report a patient with delusional parasitosis who consumed veterinary albendazole purchased on the Internet, leading to pancytopenia, transaminase elevation, and alopecia. A 53-year-old man was sent to the emergency department (ED) by his gastroenterologist because of abnormal laboratory results. The patient had chronic abdominal pain and believed he was infected with parasites. He purchased two bottles of veterinary-grade albendazole on the Internet, and over the 3 weeks before his ED visit, he consumed 113.6 g of albendazole (a normal maximal daily dose is 800 mg). Five days before admission, he noticed hair loss and a rash on his face. His examination was notable for significant scalp hair loss and hyperpigmentation along the jaw line. Laboratory studies were remarkable for pancytopenia (most notably a white blood cell count (WBC) of 0.4 × 10 cells/mm, with an absolute neutrophil count (ANC) of 0 × 10 cells/mm) and transaminase elevation (aspartate aminotransferase [AST] 268 IU/L, alanine aminotransferase [ALT] 89 IU/L). He developed a fever and was treated with antibiotics and colony-stimulating factors for presumed neutropenic bacteremia. Over the course of 1 week, his hepatic function normalized and his ANC increased to 3,000 × 10 cells/mm. Serial albendazole and albendazole sulfoxide concentrations were measured in serum and urine by liquid chromatography–quadruple time-of-flight mass spectrometry. On day 2, his serum concentrations were 20.7 ng/mL and 4,257.7 ng/mL for albendazole and albendazole sulfoxide, respectively. A typical peak therapeutic concentration for albendazole sulfoxide occuring at 2–5 hours post-ingestion is 220–1,580 ng/mL. Known adverse effects of albendazole include alopecia, transaminase elevation, and neutropenia. Pancytopenia leading to death from septic shock is reported. In our patient, prolonged use of high-dose albendazole resulted in a significant body burden of albendazole and albendazole sulfoxide, leading to pancytopenia, transaminase elevation, and alopecia. He recovered with supportive therapy.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0198
2019-11-04
2021-01-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/1/tpmd190198.html?itemId=/content/journals/10.4269/ajtmh.19-0198&mimeType=html&fmt=ahah

References

  1. Gann B, 2012. Giving patients choice and control: health informatics on the patient journey. Yearb Med Inform 7: 7073.
    [Google Scholar]
  2. Semigran HL, Linder JA, Gidengil C, Mehrotra A, 2015. Evaluation of symptom checkers for self diagnosis and triage: audit study. BMJ 351: h3480.
    [Google Scholar]
  3. Gottschall DW, Theodorides VJ, Wang R, 1990. The metabolism of benzimidazole anthelmintics. Parasitol Today 6: 115124.
    [Google Scholar]
  4. Dayan AD, 2003. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Tropica 86: 141159.
    [Google Scholar]
  5. JECFA, 1989. Albendazole: In Evaluation of Certain Veterinary Drug Residues in Food. Thirty-Fourth Report of the Joint WHO/FAO Expert Committee on Food Additives. Geneva, Switzerland: WHO.
    [Google Scholar]
  6. Mirfazaelian A, Rouini MR, Dadashzadeh S, 2002. Dose dependent pharmacokinetics of albendazole in human. Biopharm Drug Dispos 23: 379383.
    [Google Scholar]
  7. Ben Fredj N, Chaabane A, Chadly Z, Ben Fadhel N, Boughattas NA, Aouam K, 2014. Albendazole-induced associated acute hepatitis and bicytopenia. Scand J Infect Dis 46: 149151.
    [Google Scholar]
  8. Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW, 2008. Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci 23: 903905.
    [Google Scholar]
  9. Morris DL, Jourdan JL, Pourgholami MH, 2001. Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 61: 4246.
    [Google Scholar]
  10. Fernandez FJ, Rodriguez-Vidigal FF, Ledesma V, Cabanillas Y, Vagace JM, 1996. Aplastic anemia during treatment with albendazole. Am J Hematol 53: 5354.
    [Google Scholar]
  11. Opatrny L, Prichard R, Snell L, Maclean JD, 2005. Death related to albendazole-induced pancytopenia: case report and review. Am J Trop Med Hyg 72: 291294.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0198
Loading
/content/journals/10.4269/ajtmh.19-0198
Loading

Data & Media loading...

  • Received : 10 Mar 2019
  • Accepted : 12 Sep 2019
  • Published online : 04 Nov 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error